Neurocrine Biosciences, Inc. will present new analyses from a Phase 4 study at the 2025 American Association of Nurse Practitioners National Conference in San Diego. The presentation, scheduled for June 20, 2025, will highlight significant patient-reported improvements in health-related quality of life and functional measures among older adults with tardive dyskinesia treated with INGREZZA® (valbenazine) capsules. Additional presentations will include real-world insights on tardive dyskinesia and long-term improvements with valbenazine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.